Nanomedicine in autoimmunity

Drexler, 1991 Ferrari, 2005, Cancer nanotechnology: opportunities and challenges, Nat Rev Cancer, 5, 161, 10.1038/nrc1566 Whitesides, 2003, The ‘right’ size in nanobiotechnology, Nat Biotechnol, 21, 1161, 10.1038/nbt872 LaVan, 2003, Small-scale systems for in vivo drug delivery, Nat Biotechnol, 21, 1184, 10.1038/nbt876 Allkemper, 2002, Contrast-enhanced blood-pool MR angiography with optimized iron oxides: effect of size and dose on vascular contrast enhancement in rabbits, Radiology, 223, 432, 10.1148/radiol.2232010241 Chouly, 1996, Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution, J Microencapsul, 13, 245, 10.3109/02652049609026013 Pouliquen, 1991, Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolism, Magn Reson Imaging, 9, 275, 10.1016/0730-725X(91)90412-F Raynal, 2004, Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10, Invest Radiol, 39, 56, 10.1097/01.rli.0000101027.57021.28 Briley-Saebo, 2006, Clearance of iron oxide particles in rat liver: effect of hydrated particle size and coating material on liver metabolism, Invest Radiol, 41, 560, 10.1097/01.rli.0000221321.90261.09 Okon, 1994, Biodegradation of magnetite dextran nanoparticles in the rat. A histologic and biophysical study, Lab Invest, 71, 895 Rety, 2000, MR lymphography using iron oxide nanoparticles in rats: pharmacokinetics in the lymphatic system after intravenous injection, J Magn Reson Imaging, 12, 734, 10.1002/1522-2586(200011)12:5<734::AID-JMRI10>3.0.CO;2-R Zimmer, 1995, MR imaging of phagocytosis in experimental gliomas, Radiology, 197, 533, 10.1148/radiology.197.2.7480707 Schulze, 1995, Cellular uptake and trafficking of a prototypical magnetic iron oxide label in vitro, Invest Radiol, 30, 604, 10.1097/00004424-199510000-00006 Briley-Saebo, 2004, Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging, Cell Tissue Res, 316, 315, 10.1007/s00441-004-0884-8 Bourrinet, 2006, Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent, Invest Radiol, 41, 313, 10.1097/01.rli.0000197669.80475.dd Weissleder, 1989, Superparamagnetic iron oxide: pharmacokinetics and toxicity, AJR Am J Roentgenol, 152, 167, 10.2214/ajr.152.1.167 Corot, 2006, Recent advances in iron oxide nanocrystal technology for medical imaging, Adv Drug Deliv Rev, 58, 1471, 10.1016/j.addr.2006.09.013 Singh, 2010, Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION), Nano Rev, 1, 10.3402/nano.v1i0.5358 Liu, 2013, Applications and potential toxicity of magnetic iron oxide nanoparticles, Small, 9, 1533, 10.1002/smll.201201531 Mahmoudi, 2011, Assessing the in vitro and in vivo toxicity of superparamagnetic iron oxide nanoparticles, Chem Rev, 112, 2323, 10.1021/cr2002596 Naqvi, 2010, Concentration-dependent toxicity of iron oxide nanoparticles mediated by increased oxidative stress, Int J Nanomed, 5, 983, 10.2147/IJN.S13244 Hanini, 2011, Evaluation of iron oxide nanoparticle biocompatibility, Int J Nanomed, 6, 787 Jain, 2008, Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats, Mol Pharm, 5, 316, 10.1021/mp7001285 Prodan, 2013, Iron oxide magnetic nanoparticles: characterization and toxicity evaluation by in vitro and in vivo assays, J Nanomater, 2013, 10 Lubbe, 1996, Preclinical experiences with magnetic drug targeting: tolerance and efficacy, Cancer Res, 56, 4694 Siglienti, 2006, Cytokine profile of iron-laden macrophages: implications for cellular magnetic resonance imaging, J Neuroimmunol, 173, 166, 10.1016/j.jneuroim.2005.11.011 Hsiao, 2008, Macrophage physiological function after superparamagnetic iron oxide labeling, NMR Biomed, 21, 820, 10.1002/nbm.1260 Naveau, 2006, Phenotypic study of human gingival fibroblasts labeled with superparamagnetic anionic nanoparticles, J Periodontol, 77, 238, 10.1902/jop.2006.050064 Mou, 2011, Influence of synthetic superparamagnetic iron oxide on dendritic cells, Int J Nanomed, 6, 1779 Blank, 2011, Biomedical nanoparticles modulate specific CD4+ T cell stimulation by inhibition of antigen processing in dendritic cells, Nanotoxicology, 5, 606, 10.3109/17435390.2010.541293 Shen, 2012, Iron oxide nanoparticles suppressed T helper 1 cell-mediated immunity in a murine model of delayed-type hypersensitivity, Int J Nanomed, 7, 2729 Shen, 2011, A single exposure to iron oxide nanoparticles attenuates antigen-specific antibody production and T-cell reactivity in ovalbumin-sensitized BALB/c mice, Int J Nanomed, 6, 1229 Moore, 2004, Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time, Diabetes, 53, 1459, 10.2337/diabetes.53.6.1459 Tsai, 2010, Reversal of autoimmunity by boosting memory-like autoregulatory T cells, Immunity, 32, 568, 10.1016/j.immuni.2010.03.015 Yan, 2005, Liposome opsonization, J Liposome Res, 15, 109, 10.1081/LPR-64971 Immordino, 2006, Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential, Int J Nanomed, 1, 297 Drummond, 1999, Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors, Pharmacol Rev, 51, 691 Bulte, 2003, Magnetoliposomes as contrast agents, Methods Enzymol, 373, 175, 10.1016/S0076-6879(03)73012-2 De Cuyper, 1988, Magnetoliposomes formation and structural characterization, Eur Biophys J, 15, 311, 10.1007/BF00256482 Martina, 2005, Generation of superparamagnetic liposomes revealed as highly efficient MRI contrast agents for in vivo imaging, J Am Chem Soc, 127, 10676, 10.1021/ja0516460 Muller, 2009, Mechanisms of transendothelial migration of leukocytes, Circ Res, 105, 223, 10.1161/CIRCRESAHA.109.200717 Johnson-Leger, 2000, The parting of the endothelium: miracle, or simply a junctional affair, J Cell Sci, 113, 921, 10.1242/jcs.113.6.921 Papaccio, 1993, Insulitis and islet microvasculature in type 1 diabetes, Histol Histopathol, 8, 751 Jansen, 1994, Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulitis and beta-cell destruction in NOD mice, Diabetes, 43, 667, 10.2337/diab.43.5.667 Papaccio, 1998, Adhesion molecules and microvascular changes in the nonobese diabetic (NOD) mouse pancreas. An NO-inhibitor (L-NAME) is unable to block adhesion inflammation-induced activation, Autoimmunity, 27, 65, 10.3109/08916939809008037 Papaccio, 2002, Th1 and Th2 cytokines exert regulatory effects upon islet microvascular areas in the NOD mouse, J Cell Biochem, 86, 651, 10.1002/jcb.10250 Carlsson, 1998, Pancreatic islet blood perfusion in the nonobese diabetic mouse: diabetes-prone female mice exhibit a higher blood flow compared with male mice in the prediabetic phase, Endocrinology, 139, 3534, 10.1210/endo.139.8.6153 Moldovan, 1996, Glucose-induced islet hyperemia is mediated by nitric oxide, Am J Surg, 171, 16, 10.1016/S0002-9610(99)80066-X Svensson, 1994, Inhibition of nitric oxide synthase by NG-nitro-l-arginine causes a preferential decrease in pancreatic islet blood flow in normal rats and spontaneously diabetic GK rats, Endocrinology, 135, 849, 10.1210/endo.135.3.7520863 Jansson, 1986, Alloxan-induced diabetes in the mouse: time course of pancreatic B-cell destruction as reflected in an increased islet vascular permeability, Virchows Arch A Pathol Anat Histopathol, 410, 17, 10.1007/BF00710901 Sandler, 1985, Vascular permeability of pancreatic islets after administration of streptozotocin, Virchows Arch A Pathol Anat Histopathol, 407, 359, 10.1007/BF00709983 Beppu, 1987, Diabetogenic action of streptozotocin: essential role of membrane permeability, Acta Endocrinol (Copenh), 114, 90, 10.1530/acta.0.1140090 Barone, 1998, Prognostic relevance of pancreatic uptake of technetium-99m labelled human polyclonal immunoglobulins in patients with type 1 diabetes, Eur J Nucl Med, 25, 503, 10.1007/s002590050250 Denis, 2004, Imaging inflammation of the pancreatic islets in type 1 diabetes, Proc Natl Acad Sci U S A, 101, 12634, 10.1073/pnas.0404307101 Turvey, 2005, Noninvasive imaging of pancreatic inflammation and its reversal in type 1 diabetes, J Clin Invest, 115, 2454, 10.1172/JCI25048 Fu, 2011, Early window of diabetes determinism in NOD mice, dependent on the complement receptor CRIg, identified by noninvasive imaging, Nat Immunol, 13, 361, 10.1038/ni.2233 Gaglia, 2011, Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients, J Clin Invest, 121, 442, 10.1172/JCI44339 de Vries, 1997, The blood-brain barrier in neuroinflammatory diseases, Pharmacol Rev, 49, 143 Werring, 2000, The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study, Brain, 123, 1667, 10.1093/brain/123.8.1667 Kappos, 1999, Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group, Lancet, 353, 964, 10.1016/S0140-6736(98)03053-0 Lee, 1999, Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis, Brain, 122, 1261, 10.1093/brain/122.7.1261 Barkhof, 2002, The clinico-radiological paradox in multiple sclerosis revisited, Curr Opin Neurol, 15, 239, 10.1097/00019052-200206000-00003 Floris, 2004, Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study, Brain, 127, 616, 10.1093/brain/awh068 Baeten, 2008, Visualisation of the kinetics of macrophage infiltration during experimental autoimmune encephalomyelitis by magnetic resonance imaging, J Neuroimmunol, 195, 1, 10.1016/j.jneuroim.2007.11.008 Rausch, 2003, MRI-based monitoring of inflammation and tissue damage in acute and chronic relapsing EAE, Magn Reson Med, 50, 309, 10.1002/mrm.10541 Rausch, 2004, Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging, J Magn Reson Imaging, 20, 16, 10.1002/jmri.20057 Xu, 1998, Study of relapsing remitting experimental allergic encephalomyelitis SJL mouse model using MION-46L enhanced in vivo MRI: early histopathological correlation, J Neurosci Res, 52, 549, 10.1002/(SICI)1097-4547(19980601)52:5<549::AID-JNR7>3.0.CO;2-C Tysiak, 2009, Beyond blood brain barrier breakdown – in vivo detection of occult neuroinflammatory foci by magnetic nanoparticles in high field MRI, J Neuroinflamm, 6, 20, 10.1186/1742-2094-6-20 Ladewig, 2009, Spatial diversity of blood–brain barrier alteration and macrophage invasion in experimental autoimmune encephalomyelitis: a comparative MRI study, Exp Neurol, 220, 207, 10.1016/j.expneurol.2009.08.027 Vellinga, 2008, Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement, Brain, 131, 800, 10.1093/brain/awn009 Vellinga, 2009, Use of ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI to demonstrate diffuse inflammation in the normal-appearing white matter (NAWM) of multiple sclerosis (MS) patients: an exploratory study, J Magn Reson Imaging, 29, 774, 10.1002/jmri.21678 Dousset, 2006, MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium, AJNR Am J Neuroradiol, 27, 1000 Tourdias, 2012, Assessment of disease activity in multiple sclerosis phenotypes with combined gadolinium- and superparamagnetic iron oxide-enhanced MR imaging, Radiology, 264, 225, 10.1148/radiol.12111416 Muldoon, 1999, A physiological barrier distal to the anatomic blood-brain barrier in a model of transvascular delivery, AJNR Am J Neuroradiol, 20, 217 Rausch, 2002, In-vivo visualization of phagocytotic cells in rat brains after transient ischemia by USPIO, NMR Biomed, 15, 278, 10.1002/nbm.770 Dousset, 1999, In vivo macrophage activity imaging in the central nervous system detected by magnetic resonance, Magn Reson Med, 41, 329, 10.1002/(SICI)1522-2594(199902)41:2<329::AID-MRM17>3.0.CO;2-Z Desestret, 2009, Early-stage investigations of ultrasmall superparamagnetic iron oxide-induced signal change after permanent middle cerebral artery occlusion in mice, Stroke, 40, 1834, 10.1161/STROKEAHA.108.531269 Dardzinski, 2001, MR imaging of murine arthritis using ultrasmall superparamagnetic iron oxide particles, Magn Reson Imaging, 19, 1209, 10.1016/S0730-725X(01)00448-9 Beckmann, 2003, Macrophage infiltration into the rat knee detected by MRI in a model of antigen-induced arthritis, Magn Reson Med, 49, 1047, 10.1002/mrm.10480 Simon, 2006, MRI of arthritis: comparison of ultrasmall superparamagnetic iron oxide vs. Gd-DTPA, J Magn Reson Imaging, 23, 720, 10.1002/jmri.20556 Lutz, 2004, Detection of synovial macrophages in an experimental rabbit model of antigen-induced arthritis: ultrasmall superparamagnetic iron oxide-enhanced MR imaging, Radiology, 233, 149, 10.1148/radiol.2331031402 Frericks, 2009, Magnetic resonance imaging of experimental inflammatory bowel disease: quantitative and qualitative analyses with histopathologic correlation in a rat model using the ultrasmall iron oxide SHU 555C, Invest Radiol, 44, 23, 10.1097/RLI.0b013e3181899025 Maccioni, 2006, MR imaging in patients with Crohn disease: value of T2- versus T1-weighted gadolinium-enhanced MR sequences with use of an oral superparamagnetic contrast agent, Radiology, 238, 517, 10.1148/radiol.2381040244 D’Arienzo, 2001, The prognostic value, in active ulcerative colitis, of an increased intensity of colonic perivisceral fat signal on magnetic resonance imaging with ferumoxil, Am J Gastroenterol, 96, 481, 10.1111/j.1572-0241.2001.03531.x D’Arienzo, 2000, Magnetic resonance imaging with ferumoxil, a negative superparamagnetic oral contrast agent, in the evaluation of ulcerative colitis, Am J Gastroenterol, 95, 720, 10.1111/j.1572-0241.2000.01841.x Sipkins, 2000, ICAM-1 expression in autoimmune encephalitis visualized using magnetic resonance imaging, J Neuroimmunol, 104, 1, 10.1016/S0165-5728(99)00248-9 Serres, 2011, VCAM-1-targeted magnetic resonance imaging reveals subclinical disease in a mouse model of multiple sclerosis, FASEB J, 25, 4415, 10.1096/fj.11-183772 Mardiguian, 2013, Anti-IL-17A treatment reduces clinical score and VCAM-1 expression detected by in vivo magnetic resonance imaging in chronic relapsing EAE ABH mice, Am J Pathol, 182, 2071, 10.1016/j.ajpath.2013.02.029 Reynolds, 2006, Detection of vascular expression of E-selectin in vivo with MR imaging, Radiology, 241, 469, 10.1148/radiol.2412050490 Chapon, 2009, Imaging E-selectin expression following traumatic brain injury in the rat using a targeted USPIO contrast agent, MAGMA, 22, 167, 10.1007/s10334-008-0161-z Jin, 2009, Magnetic resonance molecular imaging of post-stroke neuroinflammation with a P-selectin targeted iron oxide nanoparticle, Contrast Media Mol Imaging, 4, 305, 10.1002/cmmi.292 Hu, 2005, Monitoring T-lymphocyte trafficking in tumors undergoing immune rejection, Magn Reson Med, 54, 1473, 10.1002/mrm.20717 Agger, 2007, T cell homing to tumors detected by 3D-coordinated positron emission tomography and magnetic resonance imaging, J Immunother, 30, 29, 10.1097/01.cji.0000211326.38149.7e Smirnov, 2006, In vivo cellular imaging of lymphocyte trafficking by MRI: a tumor model approach to cell-based anticancer therapy, Magn Reson Med, 56, 498, 10.1002/mrm.20996 Smirnov, 2008, In vivo single cell detection of tumor-infiltrating lymphocytes with a clinical 1.5Tesla MRI system, Magn Reson Med, 60, 1292, 10.1002/mrm.21812 Kircher, 2003, In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors, Cancer Res, 63, 6838 Yeh, 1995, In vivo dynamic MRI tracking of rat T-cells labeled with superparamagnetic iron-oxide particles, Magn Reson Med, 33, 200, 10.1002/mrm.1910330209 Yeh, 1993, Intracellular labeling of T-cells with superparamagnetic contrast agents, Magn Reson Med, 30, 617, 10.1002/mrm.1910300513 Arbab, 2004, Comparison of transfection agents in forming complexes with ferumoxides, cell labeling efficiency, and cellular viability, Mol Imaging, 3, 24, 10.1162/153535004773861697 Kalish, 2003, Combination of transfection agents and magnetic resonance contrast agents for cellular imaging: relationship between relaxivities, electrostatic forces, and chemical composition, Magn Reson Med, 50, 275, 10.1002/mrm.10556 Diana, 2013, Dose dependent side effect of superparamagnetic iron oxide nanoparticle labeling on cell motility in two fetal stem cell populations, PLoS ONE, 8, e78435, 10.1371/journal.pone.0078435 Yang, 2010, Superparamagnetic iron oxide nanoparticles may affect endothelial progenitor cell migration ability and adhesion capacity, Cytotherapy, 12, 251, 10.3109/14653240903446910 Moore, 2002, MRI of insulitis in autoimmune diabetes, Magn Reson Med, 47, 751, 10.1002/mrm.10110 Billotey, 2005, T-cell homing to the pancreas in autoimmune mouse models of diabetes: in vivo MR imaging, Radiology, 236, 579, 10.1148/radiol.2362040603 Anderson, 2004, Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis, Ann Neurol, 55, 654, 10.1002/ana.20066 Baeten, 2010, Tracking of myelin-reactive T cells in experimental autoimmune encephalomyelitis (EAE) animals using small particles of iron oxide and MRI, NMR Biomed, 23, 601, 10.1002/nbm.1501 Luchetti, 2012, Monoclonal antibodies conjugated with superparamagnetic iron oxide particles allow magnetic resonance imaging detection of lymphocytes in the mouse brain, Mol Imaging, 11, 114, 10.2310/7290.2011.00032 Pirko, 2004, In vivo magnetic resonance imaging of immune cells in the central nervous system with superparamagnetic antibodies, FASEB J, 18, 179, 10.1096/fj.02-1124fje Dearling, 2010, Detection of intestinal inflammation by MicroPET imaging using a (64)Cu-labeled anti-beta(7) integrin antibody, Inflamm Bowel Dis, 16, 1458, 10.1002/ibd.21231 Medarova, 2008, In vivo imaging of a diabetogenic CD8+ T cell response during type 1 diabetes progression, Magn Reson Med, 59, 712, 10.1002/mrm.21494 Anderson, 1999, Prevalent CD8(+) T cell response against one peptide/MHC complex in autoimmune diabetes, Proc Natl Acad Sci U S A, 96, 9311, 10.1073/pnas.96.16.9311 Verdaguer, 1997, Spontaneous autoimmune diabetes in monoclonal T cell nonobese diabetic mice, J Exp Med, 186, 1663, 10.1084/jem.186.10.1663 Trudeau, 2003, Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood, J Clin Invest, 111, 217, 10.1172/JCI200316409 Gunn, 2008, A multimodal targeting nanoparticle for selectively labeling T cells, Small, 4, 712, 10.1002/smll.200701103 Phillips, 2008, A microsphere-based vaccine prevents and reverses new-onset autoimmune diabetes, Diabetes, 57, 1544, 10.2337/db07-0507 te Boekhorst, 2012, MRI-assessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model, J Control Release, 161, 772, 10.1016/j.jconrel.2012.05.004 Wang, 2011, Combined small interfering RNA therapy and in vivo magnetic resonance imaging in islet transplantation, Diabetes, 60, 565, 10.2337/db10-1400 Wang, 2012, A theranostic small interfering RNA nanoprobe protects pancreatic islet grafts from adoptively transferred immune rejection, Diabetes, 61, 3247, 10.2337/db12-0441 Peer, 2008, Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target, Science, 319, 627, 10.1126/science.1149859 Kim, 2010, RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice, Mol Ther, 18, 370, 10.1038/mt.2009.271 Yeste, 2012, Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis, Proc Natl Acad Sci U S A, 109, 11270, 10.1073/pnas.1120611109 Getts, 2012, Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis, Nat Biotechnol, 30, 1217, 10.1038/nbt.2434 Schutz, 2008, Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells, Blood, 111, 3546, 10.1182/blood-2007-09-113522 Shen, 2011, Killer artificial antigen-presenting cells deplete alloantigen-specific T cells in a murine model of alloskin transplantation, Immunol Lett, 138, 144, 10.1016/j.imlet.2011.04.002 Perica, 2013, Nanoscale artificial antigen presenting cells for T cell immunotherapy, Nanomedicine Funkhouser, 2002, Reinventing pharma: the theranostic revolution, Curr Drug Discov, 2, 17 Evgenov, 2006, In vivo imaging of islet transplantation, Nat Med, 12, 144, 10.1038/nm1316 Evgenov, 2006, In vivo imaging of immune rejection in transplanted pancreatic islets, Diabetes, 55, 2419, 10.2337/db06-0484 Tai, 2006, Imaging islets labeled with magnetic nanoparticles at 1.5Tesla, Diabetes, 55, 2931, 10.2337/db06-0393